Scalper1 News
Two potential treatments for Duchenne muscular dystrophy inched closer to the U.S. market Monday, as BioMarin Pharmaceutical (BMRN) got an FDA decision date and Sarepta Therapeutics (SRPT) finally completed its application. BioMarin announced that the FDA had accepted its filing of drisapersen, the DMD drug it acquired with its buyout of Prosensa last year, and set itself a deadline to make a ruling by Dec. 27. Since that’s a Sunday, the decision Scalper1 News
Scalper1 News